OOIR: Observatory of International Research

Papers

(The H4-Index of Gut is 79. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Gut microbiome and health: mechanistic insights	988
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19	885
Gut microbiota-derived metabolites as central regulators in metabolic disorders	639
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN	609
Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report	548
Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome	337
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome	298
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome	247
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis	235
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) imm	233
Calprotectin: from biomarker to biological function	223
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD	208
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19	184
Helicobacter pyloriresistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community	183
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis	181
Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation	179
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting	169
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies	159
Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide	159
Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn	153
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab	146
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis	145
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer	144
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial	143
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease	141

A faecal microbiota signature with high specificity for pancreatic cancer	139
Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma	139
Diet quality and risk and severity of COVID-19: a prospective cohort study	136
Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade	135
Six-month follow-up of gut microbiota richness in patients with COVID-19	133
Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites	128
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort	126
Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis	124
Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies	124
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?	120
Recent advances in clinical practice: epidemiology of autoimmune liver diseases	120
Lactobacillus gallinarummodulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis	120
British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults	119
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma	117
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes	117
Artificial intelligence and colonoscopy experience: lessons from two randomised trials	117
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19	115
Disrupted spermatogenesis in a metabolic syndrome model: the role of vitamin A metabolism in the gut–testis axis	114
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification	113
Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice	113
Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16	113
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	111
Current therapies and new developments in NASH	109
Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis	108
Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment	106
Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic func	104
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women	103
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies	103
Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial	102
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events	102
Novel therapeutic targets for cholestatic and fatty liver disease	102
Blue poo: impact of gut transit time on the gut microbiome using a novel marker	101
Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett’s oesophagus and provides insights into clinical heterogeneity in reflux d	100
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis	97
Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity	94
Long-term yield of pancreatic cancer surveillance in high-risk individuals	93
Advancing human gut microbiota research by considering gut transit time	92
Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment	92
Chinese Consensus Report on Family-BasedHelicobacter pyloriInfection Control and Management (2021 Edition)	90
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade	90
Piecemeal cold snare polypectomy versus conventional endoscopic mucosal resection for large sessile serrated lesions: a retrospective comparison across two successive periods	89
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulce	89
FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2	87
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis	86
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future	83
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update	83
Methionine deficiency facilitates antitumour immunity by altering m⁶A methylation of immune checkpoint transcripts	82
Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts	82
CXCR2 inhibition enables NASH-HCC immunotherapy	82
Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer	81

Estimating the environmental impact of disposable endoscopic equipment and endoscopes	80
Targeting m⁶A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer	80
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis	80
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39⁺CD8⁺ T cells	79
Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases	79